Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;25(6):1131-1132.
doi: 10.1007/s10120-022-01336-3. Epub 2022 Sep 26.

PD-L1 IHC testing: issues with interchangeability evidence based on laboratory-developed assays of unknown analytical performance

Emina Emilia Torlakovic  1
Affiliations
Comment

PD-L1 IHC testing: issues with interchangeability evidence based on laboratory-developed assays of unknown analytical performance

Emina Emilia Torlakovic. Gastric Cancer. 2022 Nov.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Yeong J, Lum HYJ, Teo CB, et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer. 2022;25:741–50. - DOI
    1. Yeong J, Tan T, Chow ZL, Cheng Q, Lee B, Seet A, Lim JX, Lim JCT, Ong CCH, Thike AA, Saraf S, Tan BYC, Poh YC, Yee S, Liu J, Lim E, Iqbal J, Dent R, Tan PH. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC. J Clin Pathol. 2020;73:557–62. - DOI
    1. Takeda M, Kasai T, Naito M, Tamiya A, Taniguchi Y, Saijo N, Naoki Y, Okishio K, Shimizu S, Kojima K, Nagoya A, Sakamoto T, Utsumi T, Yoon HE, Matsumura A, Atagi S. programmed death-ligand 1 expression with clone 22c3 in non-small cell lung cancer: a single institution experience. Clin Med Insights Oncol. 2019;9(13):1179554918821314.
    1. Gagné A, Wang E, Bastien N, Orain M, Desmeules P, Pagé S, Trahan S, Couture C, Joubert D, Joubert P. Impact of specimen characteristics on pd-l1 testing in non-small cell lung cancer: validation of the IASLC PD-L1 testing Recommendations. J Thorac Oncol. 2019;12:2062–70. - DOI
    1. Cheung CC, Smith AC, Albadine R, Bigras G, Bojarski A, Couture C, Cutz JC, Huang WY, Ionescu D, Itani D, Izevbaye I, Karsan A, Kelly MM, Knoll J, Kwan K, Nasr MR, Qing G, Rashid-Kolvear F, Sekhon HS, Spatz A, Stockley T, Tran-Thanh D, Tucker T, Waghray R, Wang H, Xu Z, Yatabe Y, Torlakovic EE, Tsao MS. Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. Lung Cancer. 2021;160:127–35. - DOI

LinkOut - more resources